ABSTRACT

Background The long-term natural history of chronic obstructive pulmonary disease (COPD) in terms of successive severe exacerbations and mortality is unknown.

Methods The authors formed an inception cohort of patients from their first ever hospitalisation for COPD during 1990–2005, using the healthcare databases from the province of Quebec, Canada. Patients were followed until death or 31 March 2007, and all COPD hospitalisations occurring during follow-up were identified. The hazard functions of successive hospitalised COPD exacerbations and all-cause mortality over time were estimated, and HRs adjusted for age, sex, calendar time and comorbidity.

Results The cohort included 73 106 patients hospitalised for the first time for COPD, of whom 50 580 died during the 17-year follow-up, with 50% and 75% mortality at 3.6 and 7.7 years respectively. The median time from the first to the second hospitalised exacerbation was around 5 years and decreased to <4 months from the 9th to the 10th. The risk of the subsequent severe exacerbation was increased threefold after the second severe exacerbation and 24-fold after the 10th, relative to the first. Mortality after a severe exacerbation peaked to 40 deaths per 10 000 per day in the first week after admission, dropping gradually to 5 after 3 months.

Conclusions The course of COPD involves a rapid decline in health status after the second severe exacerbation and high mortality in the weeks following every severe exacerbation. Two strategic targets for COPD management should include delaying the second severe exacerbation and improving treatment of severe exacerbations to reduce their excessive early mortality.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD), characterised by progressive, generally irreversible, airflow limitation associated with an abnormal inflammatory response of the lungs, has been increasing in prevalence, affecting over 12 million people in the USA alone, where it has become the third leading cause of death. While the disease course involves a slow progressive deterioration in airflow, it is punctuated by exacerbations, many of which are serious, requiring hospitalisation and associated with higher mortality and elevated costs.

The progressive deterioration in COPD has traditionally been illustrated by the Fletcher-Peto curves that suggest a smooth continuous acceleration of decay in lung function over time. Such a gradual decay in forced expiratory volume in 1 s (FEV1) inherently implies that exacerbations interspersed within the course of disease do not necessarily alter this natural history. Y et, recent studies report an association between exacerbations and a greater decline in lung function. Moreover, increasing exacerbation frequency has been associated with higher mortality, while exacerbations appear to cluster in time, and a history of exacerbations is the single best predictor of future exacerbations. Thus, rather than the smooth gradual decay suggested by the Fletcher-Peto curves, these findings evoke more a stepwise component to the deterioration in COPD over time. Such a hypothesis, however, is uncertain as all natural history studies have been based on prevalent cohorts where disease duration is not considered and the first COPD exacerbation under study is seldom the first in the patient’s course of disease. As a result, the natural course of COPD over the long term remains largely unknown, particularly as it relates to its duration, the impact of successive exacerbations and the effect on mortality, two major outcomes of this disease.

We use a large population-based inception cohort of patients from their first severe COPD...
exacerbation to describe the long-term profile of severe COPD exacerbations over time and their association with mortality.

**Methods**

**Data source**

We used the computerised databases of the Régie de l’assurance maladie du Québec (RAMQ) from the health insurance program of the province of Québec, Canada for its 7 million residents. The databases include information on demographics and all medical services rendered, including hospitalisations in acute care hospitals. For people aged 65 years or older, social welfare recipients and, since 1996, residents who choose to join the provincial drug plan, the prescription drugs database includes all dispensed outpatient prescription medications. The RAMQ Databases, linked by a unique health insurance number, have been used previously to conduct several epidemiological studies, including studies in COPD.13–18

**Study cohort**

We first identified all subjects who, during 1990–2005, were dispensed at least one prescription for respiratory medications including β agonists, theophylline, ipratropium bromide, tiotropium, inhaled corticosteroid, nedocromil, ketotifen, cromolyn or anti-leukotriene. After the first prescription for a respiratory medication, we formed the cohort of all patients with a first severe COPD exacerbation, defined as their first hospitalisation with a primary discharge diagnosis of COPD (International Classification of Diseases ninth revision (ICD-9) codes 490–492 and 496, ICD-10 codes J40–J44). To increase the likelihood of a correct diagnosis, we excluded subjects aged <55 years at the time of this first hospitalisation and those with a prior asthma hospitalisation. Cohort members were followed from this first hospitalisation for COPD until death or 31 March 2007. All severe exacerbations, defined as subsequent hospitalisations with a primary discharge diagnosis of COPD, occurring during follow-up, were identified.

**Data analysis**

Cohort entry was defined differently for the two study outcomes, namely severe exacerbation and mortality. To analyse the rate of a subsequent severe exacerbation, cohort entry was defined as the date of live discharge from hospital while, to study mortality, cohort entry was defined as the date of admission to account for the fact that patients were at risk of death during a COPD hospitalisation.

For the analysis of mortality, the Kaplan–Meier technique was first used to estimate the cumulative incidence function of time to death from cohort entry. To assess the effect of each successive severe exacerbation on mortality, a Cox proportional hazards model was used to estimate the hazard ratio (HR) of death as a function of the severe exacerbation sequence number occurring during follow-up time, included as a time-dependent

---

**Figure 1** Flowchart of cohort formation. COPD, chronic obstructive pulmonary disease.
factor to consider its timing, relative to the hazard of death after the first severe exacerbation. Age in years, sex, calendar time of cohort entry (before or after the year 2000 to account for changes in patient management) and comorbidity measured at cohort entry were also included as adjustment factors for this effect. Comorbidity was measured using the modified Von Korff chronic disease score, devised specifically for healthcare databases, divided into quartiles. Age and sex were not included in the score to allow estimation of their independent effects. The same Cox proportional hazards model approach was also used to estimate the effect of each successive severe exacerbation on the subsequent one, with a time-dependent factor to account for the timing of each severe exacerbation over follow-up time.

The overall hazard function of the successive severe exacerbations was estimated in two steps. First, to estimate the inter-exacerbation times, the cohort of patients discharged alive from their first ever COPD hospitalisation was followed until the earliest of the dates of admission for the second severe COPD exacerbation, death or the end of the observation period. This follow-up to the next severe exacerbation was repeated after each severe exacerbation. The median time from each severe exacerbation to the next was estimated using the Kaplan–Meier technique modified for competing risks to account for deaths occurring before the next severe exacerbation. An additional approach to account for deaths was based on estimating the median time between live discharge and the date of admission for the next severe COPD exacerbation or death, whichever occurred first, using the Kaplan–Meier technique. Second, the life-table approach was used to estimate the hazard function over time of a subsequent severe exacerbation after each severe exacerbation. Thus, the hazard functions of each successive severe exacerbation were combined with the respective median inter-exacerbation times to graphically express the hazard function of successive severe exacerbations over time.

RESULTS

There were 1 410 211 people dispensed respiratory medications during 1990–2005, resulting in a study cohort of 73 106 patients admitted for their first severe exacerbation of COPD requiring hospitalisation (figure 1). At cohort entry, the subjects had a mean age of 75 years (IQR 70–81) and 54% were men, with the majority having received bronchodilators, corticosteroids or theophylline in the year prior to the first COPD hospitalisation (table 1), and 6.3% having used smoking cessation medications.

During the mean follow-up of 3.6 years (range 1 day to 17 years), 33 166 patients had at least one subsequent severe exacerbation requiring hospitalisation and 50 580 died (baseline characteristics in table 1). The mean rate of severe exacerbation requiring hospitalisation was 37.8 per 100 per year, while the mortality rate was 19.2 per 100 per year. While the mean age at the initial cohort entry exacerbation was 75 years, it remained practically the same at 75 years at the time of each subsequent severe exacerbation, an effect of age-related mortality. Figure 2 shows the cumulative mortality over the 17-year follow-up period, with a median survival of 3.6 years, 75% mortality at 7.7 years and 96% mortality by 17 years.

Figure 5A displays the hazard function of the time to the next severe exacerbation for the first 10 severe exacerbations after the first COPD hospitalisation. This graph illustrates three aspects of the risk. First, the median time between successive severe exacerbations decreases with every new severe exacerbation, from around 5.4 years from the first to the second to <4 months from the 9th to the 10th. However, figure 3B finds a similar pattern, but a shorter time span between severe exacerbations and the earliest of the next severe exacerbation or death. Second, when the patient is discharged after each severe exacerbation, the risk of the next severe exacerbation peaks during the trimester following discharge, jumping by 30–40 severe exacerbations per 10 000 per day, decreasing significantly thereafter to a lower baseline rate. Third, the baseline rate of a severe exacerbation increases with every new severe exacerbation, increasing from a baseline rate of around 3 per 10 000 per day for the first severe exacerbation to 50 per 10 000 per day for the 9th severe exacerbation.

Table 2 quantifies these increases, showing that the rate of a subsequent severe exacerbation is three times higher after the

| Table 1 | Patient characteristics at cohort entry for the entire cohort defined by the first hospitalisation for a chronic obstructive pulmonary disease (COPD) exacerbation, for those patients with subsequent COPD exacerbations and for those who died during follow-up |
|---|---|---|
| | Entire cohort | At least one subsequent exacerbation | Deaths |
| Number | 73 106 | 33 166 | 50 580 |
| Age at cohort entry (years; mean±SD) | 75.4±8.4 | 73.9±7.9 | 76.4±8.1 |
| Men (%) | 54.5 | 56.7 | 59.0 |
| Cohort entry after year 2000 (%) | 42.5 | 32.0 | 28.2 |
| Respiratory medications in the year prior to cohort entry* (%) | | | |
| Short-acting β agonists | 80.0 | 87.1 | 81.6 |
| Long-acting β agonists | 15.5 | 14.4 | 10.1 |
| Ipratropium bromide | 46.6 | 51.9 | 46.4 |
| Tiotropium | 2.2 | 1.4 | 0.8 |
| Inhaled corticosteroids | 59.4 | 65.9 | 58.0 |
| Oral corticosteroids | 33.5 | 38.7 | 32.2 |
| Theophylline | 29.2 | 37.0 | 36.1 |
| Respiratory antibiotics | 60.3 | 63.0 | 61.4 |
| Modified Chronic Disease Score* (% | | | |
| First quartile | 24.8 | 24.7 | 25.3 |
| Second quartile | 25.1 | 27.0 | 25.5 |
| Third quartile | 25.1 | 25.8 | 25.2 |
| Fourth quartile | 25.0 | 22.5 | 24.0 |

*At least one dispensed prescription among the 94% of patients with available medication information in the year prior to cohort entry.


---

**Figure 2** Kaplan–Meier survival function for the cohort of 73 106 patients from the time of their first ever hospitalisation for a chronic obstructive pulmonary disease exacerbation over the 17-year follow-up period.
higher than after the first, while after the 10th it is five times higher than after the first, all after adjusting for age, sex, calendar time and comorbidity.

Table 3 shows the impact of age, sex, calendar time and the comorbidity index on the rate of a subsequent exacerbation and of death. The rate of exacerbation decreases by 10% with each additional decade of age, while the rate of death increases by 66% with each decade. Men have higher rates of exacerbation and mortality than women, while patients having their first exacerbation after the year 2000 have lower rates of subsequent exacerbations and mortality than those prior to 2000. In particular, the median time from the first to the second severe exacerbation is higher at 7.2 years in patients who enter the cohort after the year 2000 compared with 4.2 years before 2000, while it is 7.1 years for women and 4.4 years for men, and 13.2 years for patients over the age of 75 at cohort entry versus 3.9 years for those younger than 75. Moreover, the median time from the first to the second severe exacerbation or death is 1.9 years in patients who enter the cohort after the year 2000 versus 1.5 years before 2000, 2.1 years for women and 1.4 years for men, and 1.5 years for patients over the age of 75 at cohort entry versus 1.8 years for those younger than 75. Patients with more comorbidity also have higher incidences of these outcomes.

Figure 4 magnifies, after each of the first 10 severe exacerbations, the first year of the hazard function of the time to the next severe exacerbation shown in figure 2. It shows that the rate of the next severe exacerbation systematically increases after each new severe exacerbation, peaking in the month after discharge and remaining more elevated for around 3 months. It also shows that this peak rises higher with every new severe exacerbation number and its timing

**Table 2** Crude and adjusted hazard ratio (HR) of a subsequent exacerbation and of death associated with each successive exacerbation, as a function of the time since the first exacerbation, estimated by Cox proportional hazards model with time-dependent covariate defining the exacerbation number and its timing

**Table 3** Adjusted hazard ratio (HR) of a subsequent exacerbation and of death associated with age, sex, calendar time of cohort entry and quartiles of the modified Chronic Disease Score by Cox proportional hazards model with time-dependent covariate defining the exacerbation number

<table>
<thead>
<tr>
<th>Exacerbation sequence number</th>
<th>Median time to subsequent exacerbation (years)</th>
<th>Number with a subsequent exacerbation</th>
<th>Crude HR</th>
<th>Adjusted* HR (95% CI)</th>
<th>Number of deaths</th>
<th>Crude HR</th>
<th>Adjusted* HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First (reference)</td>
<td>5.4</td>
<td>33 166</td>
<td>1.0</td>
<td>1.0 (reference)</td>
<td>25 953</td>
<td>1.0</td>
<td>1.0 (reference)</td>
</tr>
<tr>
<td>Second</td>
<td>1.6</td>
<td>19 359</td>
<td>3.0</td>
<td>2.9 (2.8 to 2.9)</td>
<td>9828</td>
<td>1.8</td>
<td>1.9 (1.8 to 1.9)</td>
</tr>
<tr>
<td>Third</td>
<td>0.9</td>
<td>12 413</td>
<td>5.1</td>
<td>4.9 (4.8 to 5.0)</td>
<td>5203</td>
<td>2.4</td>
<td>2.4 (2.3 to 2.5)</td>
</tr>
<tr>
<td>Fourth</td>
<td>0.7</td>
<td>8374</td>
<td>7.3</td>
<td>6.6 (6.5 to 7.1)</td>
<td>3078</td>
<td>2.8</td>
<td>2.9 (2.8 to 3.0)</td>
</tr>
<tr>
<td>Fifth</td>
<td>0.5</td>
<td>5903</td>
<td>9.8</td>
<td>9.2 (8.9 to 9.4)</td>
<td>1879</td>
<td>3.0</td>
<td>3.2 (3.0 to 3.4)</td>
</tr>
<tr>
<td>Sixth</td>
<td>0.4</td>
<td>4316</td>
<td>11.9</td>
<td>11.2 (10.8 to 11.5)</td>
<td>1207</td>
<td>3.1</td>
<td>3.3 (3.1 to 3.5)</td>
</tr>
<tr>
<td>Seventh</td>
<td>0.3</td>
<td>3190</td>
<td>13.9</td>
<td>13.0 (12.5 to 13.5)</td>
<td>872</td>
<td>3.4</td>
<td>3.6 (3.4 to 3.9)</td>
</tr>
<tr>
<td>Eighth</td>
<td>0.3</td>
<td>2404</td>
<td>16.6</td>
<td>15.2 (14.6 to 15.9)</td>
<td>645</td>
<td>3.9</td>
<td>4.2 (3.9 to 4.5)</td>
</tr>
<tr>
<td>Ninth</td>
<td>0.3</td>
<td>1823</td>
<td>18.1</td>
<td>16.6 (15.8 to 17.4)</td>
<td>470</td>
<td>3.8</td>
<td>4.3 (3.9 to 4.7)</td>
</tr>
<tr>
<td>Tenth or greater</td>
<td>0.2</td>
<td>1403</td>
<td>25.8</td>
<td>23.5 (22.8 to 24.2)</td>
<td>1445</td>
<td>4.5</td>
<td>5.2 (4.9 to 5.5)</td>
</tr>
</tbody>
</table>

*Adjusted for age, sex, calendar time (cohort entry prior to 2000), and the modified Chronic Disease Score divided in quartiles with a fifth category to account for subjects with no or partial medication information in the year prior to cohort entry.
TABLE 4  

<table>
<thead>
<tr>
<th>Exacerbation sequence number</th>
<th>Exacerbation Mortality</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Crude HR</td>
<td>Adjusted* HR (95% CI)</td>
</tr>
<tr>
<td>First (reference)</td>
<td>1.00</td>
<td>1.00 (reference)</td>
</tr>
<tr>
<td>Second</td>
<td>1.78</td>
<td>1.76 (1.73 to 1.80)</td>
</tr>
<tr>
<td>Third</td>
<td>2.36</td>
<td>2.32 (2.27 to 2.37)</td>
</tr>
<tr>
<td>Fourth</td>
<td>2.86</td>
<td>2.79 (2.72 to 2.86)</td>
</tr>
<tr>
<td>Fifth</td>
<td>3.32</td>
<td>3.22 (3.13 to 3.32)</td>
</tr>
<tr>
<td>Sixth</td>
<td>3.71</td>
<td>3.60 (3.48 to 3.71)</td>
</tr>
<tr>
<td>Seventh</td>
<td>3.97</td>
<td>3.85 (3.71 to 3.99)</td>
</tr>
<tr>
<td>Eighth</td>
<td>4.42</td>
<td>4.23 (4.06 to 4.41)</td>
</tr>
<tr>
<td>Ninth</td>
<td>4.60</td>
<td>4.41 (4.20 to 4.62)</td>
</tr>
<tr>
<td>Tenth or greater</td>
<td>5.47</td>
<td>5.21 (5.07 to 5.36)</td>
</tr>
</tbody>
</table>

*Adjusted for age, sex, calendar time (cohort entry prior to 2000), and the modified Chronic Disease Score divided in quartiles with a fifth category to account for subjects with no or partial medication information in the year prior to cohort entry.
We found that mortality peaks drastically during the 3-month period following the onset of a severe exacerbation, and of the same magnitude after each severe exacerbation, including the very first one.

A strength of our study is that we studied an inception cohort of patients from their first severe COPD exacerbation. Previous epidemiological studies of this natural history were based on cohorts of patients with prevalent COPD, in which the first exacerbation under study is rarely the first ever. Thus, patients are compared at different time points in their disease course which can introduce bias in several ways. First, the frequency of exacerbations at cohort entry could reflect disease duration rather than disease severity. Indeed, patients with no exacerbations in a year could be early in their disease course while patients with multiple exacerbations could have had the disease for a long time, making it likely that part of the apparent differences in phenotypes of patients with and without frequent exacerbations is due to comparing patients at different points in the natural history of their disease. Second, prevalent cohorts exclude patients who die of their first or second exacerbation and do not make it into the cohort, introducing the possibility of selection bias which can exaggerate the association between the number of exacerbations and mortality.

A limitation of our study is the lack of information on the severity of symptoms, airflow limitation and exercise intolerance. Also the diagnosis of COPD cannot be verified directly either through the medical chart or records of lung function. The identification of patients with COPD was based on the primary discharge diagnosis listed for a hospitalisation, previously shown to be valid in the database used in the current study. To further distinguish COPD from asthma, we excluded subjects with an asthma hospitalisation prior to the first COPD hospitalisation and included only subjects whose first COPD hospitalisation occurred after the age of 55 years.

The clinical implications of these findings are important. First, mortality in the first 7 days of a hospitalisation for COPD is very high and therefore this at-risk period deserves special attention. A recent audit of COPD hospitalisations in the UK found the use of non-invasive ventilation to be suboptimal. Of the therapies given in this critical period, systemic corticosteroids have not shown a benefit on mortality, while to date, studies of antibiotics show promise. For those who survive, the risk of exacerbation continued to be very high for the first 3 months before settling to a baseline rate. This 3-month period might be amenable to a reduction in risk that may be provided by transitional care programmes.

In all, this natural history study has identified two strategic targets for the management of patients with COPD, namely delaying the second severe exacerbation and improving the treatment of all severe exacerbations to reduce the associated excessive early mortality. Our results support the call for increased attention to the treatment and prevention of ‘lung attacks’ in patients with COPD.

Acknowledgements The authors thank the Commission d’accès à l’information du Québec for allowing access to the data and agents from the Régie de l’assurance maladie du Québec (RAMQ) for sending the database.

Contributors SS acquired the data. SS, SD and PE participated in the analysis. SS wrote the article. All authors had full access to the data and SS takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This research was funded by grants from the Canadian Institutes of Health Research (CIHR), the Canadian Foundation for Innovation (CFI) and support from Boehringer-Ingelheim.

Competing interests None.

Ethics approval Ethics approval was provided by Ethics Board of the Jewish General Hospital.
REFERENCES


Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality
Samy Suissa, Sophie Dell'Aniello and Pierre Ernst

Thorax 2012 67: 957-963 originally published online June 8, 2012
doi: 10.1136/thoraxjnl-2011-201518

Updated information and services can be found at:
http://thorax.bmj.com/content/67/11/957

These include:

References
This article cites 34 articles, 10 of which you can access for free at:
http://thorax.bmj.com/content/67/11/957#BIBL

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. The use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Editor's choice (125)
Open access (244)
Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/